Pacific Edge (ASX:PEB, NZE:PEB) noted that the "Genetic Testing in Oncology: Specific Tests" local coverage determination became effective on April 24 in the US, halting Medicare coverage of its Cxbladder tests, according to Monday's Australian and New Zealand bourse filings.
A Pennsylvania District Court Judge ruled that her court lacks the jurisdiction to hear the firm's claim against Medicare administrative contractor Novitas and the US Centers for Medicare and Medicaid Services.
Its advocacy efforts also did not yield a change to the effective date or retirement of the local coverage determination.
Pacific Edge currently generates around 60% of its US revenue from Medicare. It will not seek re-coverage of Cxbladder Detect as no new evidence has been published that can be submitted for reconsideration. Detect users will be required to move over to the Triage test.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.